Please Subscribe to get a daily link to Pat's blog via email

Subscribe!

Your privacy is important to us. We will never spam you and keep your personal data secure.

refractory

Home/Tag:refractory
21 01, 2012

Is pomalidomide a wonder drug? Depends how you spin it…

Tags: , , , , , |4 Comments

OncologySTAT ran this feature article about pomalidomide last week in their hematology edition.  Here are a few excerpts: Pomalidomide Elicits Responses When Other Myeloma Regimens Fail By P. Wendling SAN DIEGO - The potent, next-generation immunomodulatory inhibitor pomalidomide works in at least one-third of patients with relapsed and/or refractory multiple myeloma when nothing else does,

11 12, 2011

Full coverage of Friday evening IMF Satellite Symposium event (Part Three)

Tags: , , , , , , , , , , , , |1 Comment

I know, I know.  I'm falling behind!  I'm so busy collecting and analyzing newly released myeloma related research data, I have barely had time to write. Here is the final installment of my three part report about the IMF's Friday evening Satellite Symposium. I saved the best for last!  Dr. Robert Orlowski with M.D. Anderson

13 11, 2011

TIP: Understanding the difference between “time to disease progression” and “median life expectancy”

Tags: , , , |4 Comments

Time to disease progression and median life expectancy are the two primary measurements used to evaluate how well a new anti-myeloma therapy is working. Time to disease progression refers to how long it takes for a patient's multiple myeloma to return after they start using a therapy. Median life expectancy measures how long a patient

3 03, 2011

A Bit Of Positive News During An Otherwise Slow Myeloma-Related News Cycle

Tags: , , , , , , |2 Comments

Multiple myeloma news runs in cycles and streaks.  The calendar revolves around the two largest U.S. hematology and oncology conferences:  The American Society of Clinical Oncologists (ASCO) meetings in June, and the American Society of Hematology (ASH) meetings in December.That is where researchers and drug companies present their most important study results.  Starting as early as

9 12, 2010

Pomalidomide Studies Continues To Progress & Impress

Tags: , , , , |0 Comments

Good morning!  I have neglected reporting about pomalidomide.  This new, experimental, novel therapy agent continues to impress in a slow, deliberate way.No negative surprises (so far!) that I can see.  Very good responses in patients refractory to Velcade and Revlimid.  Here is an example of an abstract provided by Celgene yesterday:Abstract #863 – Pomalidomide Plus

2 12, 2010

Continued Good News From Mayo Clinic Pomalidomide (CC4047) Studies

Tags: , , , |0 Comments

This is very good news as posted on OncologySTAT yesterday:Pomalidomide (CC4047) Plus Low Dose Dexamethasone (Pom/dex) is Active and Well Tolerated In Lenalidomide Refractory Multiple Myeloma (MM)Leukemia. 2010 Nov 1;24(11):1934-1939, MQ Lacy, SR Hayman, MA Gertz, KD Short, A Dispenzieri, S Kumar, PR Greipp, JA Lust, SJ Russell, D Dingli, S Zeldenrust, R Fonseca, PL

8 11, 2010

More from Dr. Stewart About Treatment and Clinical Study Options For Multiple Myeloma Patients Who Have Become Resistant To Revlimid And/Or Velcade Therapy

Tags: , , , , , , , , , , , |0 Comments

Yesterday I shared Dr. Stewart's hopeful message to patients for whom Revlimid and Velcade no longer work.  Here is his response to the question: Should I consider a clinical trial? What new therapies in clinical trials look promising?  as posted on the Multiple Myeloma Research Foundation (MMRF) site recently:Clinical trials are an important option for patients who

26 07, 2010

Monday Morning Press Conference Notes About Phase 2 Trial Results For Onyx Pharmaceutical’s New Anti-Myeloma Drug, Carfilzomib

Tags: , , , , , |0 Comments

I just concluded attending an online press conference with officials from Onyx Pharmaceuticals, manufacturers of the experimental anti-myeloma drug, carfilzomib.This was primarily a business related press conference, especially the Q & A portion at the end. Since journalists weren't presented a written transcript, I will keep the details basic. You can expect a follow-up soon

25 07, 2010

New Pomalidomide Study Available To Multiple Myeloma Patients Who’s Revlimid Has Stopped Working

Tags: , , , , , , , |0 Comments

Since it may be two or three years until Celgene's oral anti-myeloma novel therapy agent, pomalidomide, is approved by the FDA and widely available, patients with relapsed and/or refractory multiple myeloma may want to consider getting involved in a pomalidomide related clinical study.If you have tried Revlimid and it is no longer working you may

10 07, 2010

INK 128: Another Example Of An Anti-Cancer Compound Which Shows Potential Against Multiple Myeloma

Tags: , , |1 Comment

Yesterday I wrote about perifisone.  This exciting new anti-cancer compound is being tested on several types of cancer in addition to multiple myeloma.  Here is another example of a new crossover cancer drug.  INK128 is a novel, orally available small molecule inhibitor of the TORC1 and TORC2 complexes, key components of the PI3K/mTOR signaling pathway,

18 05, 2010

Reflections From A Caregiver: "In this cancer community of survivors, how do we promote the power of positive thinking and not leave behind those who’s treatments are failing to impact the disease?"

Tags: , , , , , , , |0 Comments

I have been e-mailing back and forth with a caregiver named Kate.  She originally contacted me about an article I wrote last week, An Ambiguous Multiple Myeloma Maintenance Therapy Study Is Still Worth A Look.  As I often do, I was commenting on one of the numerous research studies I often read.  Here is the

1 03, 2010

Enough About Me! Watch For Other Choices/Options For Treating Refractory Multiple Myeloma

Tags: , |0 Comments

Enough about me!  Unless something drastically changes, yesterday I outlined my likely steps towards treating my refractory (relapsed) multiple myeloma.  To help all of us prepare for the day when our myeloma begins to get worse instead of better, I have enrolled in an oncology course titled: Relapsed/Refractory Multiple Myeloma: Options for Subsequent Therapy.  The

5 12, 2009

Live! Five Different Presentations & Panel Discussion From ASH In New Orleans

Tags: , , , , , , , |4 Comments

Program Director Dr. Brian Durie has just introduced tonight's panel: Dr. Mario Boccadoro from Italy, Dr. Philippe Moreau from France, Dr. Robert Orlowski with M.D. Anderson Cancer Centers and Dr. Vincent Rajkumar from Mayo Clinic. 400+ docs, researchers, drug reps, oncology nurses and a few of us patients, fill the room. The presentations have begun.